title: A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
abstract: OBJECTIVE
  Systemic chemotherapy fails to access much of the tumor burden in patients with advanced cancer, significantly limiting its efficacy. In preclinical studies, brief high doses of tyrosine kinase inhibitors (TKI) targeting the human epidermal growth factor receptor (HER) family can prime tumor vasculature for optimal chemotherapeutic delivery and efficacy. This study investigates the clinical relevance of this approach.
  
  
  METHODS
  A phase I clinical study of escalating doses of the HER TKI lapatinib given as a 2-day pulse before a weekly infusion of nab-paclitaxel (100 mg/m(2)) was conducted in patients with advanced solid tumors.
  
  
  RESULTS
  Twenty-five patients were treated. Treatment was associated with grade 1 to 2 toxicities including diarrhea, nausea, rash, neutropenia, neuropathy, fatigue, alopecia, and anemia. The two dose-limiting toxicities were grade 3 vomiting and grade 4 neutropenia, and the maximum tolerated dose of lapatinib was defined as 5250 mg/day in divided doses. Lapatinib concentrations increased with increasing dose. Dynamic Contrast Enhanced Magnetic Resonance Imaging studies in a subset of patients confirmed a decrease in tumor vascular permeability immediately following a lapatinib pulse. Sixty-five percent of evaluable patients experienced a partial or stable response on this therapy, 72% of whom were previously taxane-refractory.
  
  
  CONCLUSIONS
  A 2-day pulse of high-dose lapatinib given before weekly nab-paclitaxel is a feasible and tolerable clinical regimen, suitable for testing this novel vascular-priming chemosensitization hypothesis developed in preclinical models.
authors.affiliation: Department of Medicine, University of California San Francisco, San Francisco, California 94143-0875, USA.
authors.forename: Amy J
authors.initials: AJ
authors.lastname: Chien
authors.forename: Julie A
authors.initials: JA
authors.lastname: Illi
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Ko
authors.forename: Wolfgang M
authors.initials: WM
authors.lastname: Korn
authors.forename: Lawrence
authors.initials: L
authors.lastname: Fong
authors.forename: Lee-may
authors.initials: LM
authors.lastname: Chen
authors.forename: Mohammed
authors.initials: M
authors.lastname: Kashani-Sabet
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Ryan
authors.forename: Jonathan E
authors.initials: JE
authors.lastname: Rosenberg
authors.forename: Sarita
authors.initials: S
authors.lastname: Dubey
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Small
authors.forename: Thierry M
authors.initials: TM
authors.lastname: Jahan
authors.forename: Nola M
authors.initials: NM
authors.lastname: Hylton
authors.forename: Benjamin M
authors.initials: BM
authors.lastname: Yeh
authors.forename: Yong
authors.initials: Y
authors.lastname: Huang
authors.forename: Kevin M
authors.initials: KM
authors.lastname: Koch
authors.forename: Mark M
authors.initials: MM
authors.lastname: Moasser
mesh_terms: D000284:Administration, Oral; D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols; D004305:Dose-Response Relationship, Drug; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D000077341:Lapatinib; D008297:Male; D008875:Middle Aged; D053758:Nanoparticles / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D011799:Quinazolines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077341:Lapatinib; D066246:ErbB Receptors; D017239:Paclitaxel
references.citation: J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47
references.pmid: 9262252
references.citation: Cancer Chemother Pharmacol. 1999;44(3):241-8
references.pmid: 10453726
references.citation: J Clin Oncol. 2005 May 20;23(15):3502-8
references.pmid: 15908660
references.citation: Cancer Res. 1999 Apr 1;59(7):1454-7
references.pmid: 10197613
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5305-13
references.pmid: 15955900
references.citation: Neoplasia. 2007 Dec;9(12):1066-77
references.pmid: 18084614
references.citation: Science. 2005 Jan 7;307(5706):58-62
references.pmid: 15637262
references.citation: Cancer Res. 1996 May 1;56(9):2112-5
references.pmid: 8616858
references.citation: Pharm Res. 2005 Jun;22(6):867-74
references.pmid: 15948030
references.citation: J Clin Oncol. 2004 Mar 1;22(5):785-94
references.pmid: 14990633
references.citation: Cancer Res. 2006 Feb 15;66(4):2173-80
references.pmid: 16489018
references.citation: Cancer Res. 2004 Jun 1;64(11):3731-6
references.pmid: 15172975
references.citation: Circ Res. 2002 Jun 28;90(12):1243-50
references.pmid: 12089061
references.citation: J Clin Oncol. 2004 Mar 1;22(5):777-84
references.pmid: 14990632
references.citation: Am J Pathol. 2002 Sep;161(3):929-38
references.pmid: 12213721
references.citation: Neoplasia. 2008 May;10(5):489-500
references.pmid: 18472966
references.citation: Cancer Chemother Pharmacol. 2001 Apr;47(4):309-18
references.pmid: 11345647
references.citation: Radiology. 2003 Dec;229(3):885-92
references.pmid: 14576446
references.citation: N Engl J Med. 2006 Dec 14;355(24):2542-50
references.pmid: 17167137
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7785-93
references.pmid: 16258082
references.citation: N Engl J Med. 2007 Dec 27;357(26):2666-76
references.pmid: 18160686
references.citation: Br J Cancer. 1999 Sep;81(2):330-5
references.pmid: 10496361
references.citation: Nature. 2004 Feb 19;427(6976):695
references.pmid: 14973470
references.citation: Rapid Commun Mass Spectrom. 2004;18(3):285-92
references.pmid: 14755613
references.citation: Cancer Chemother Pharmacol. 2007 Mar;59(4):467-75
references.pmid: 16896930
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Cell Signal. 2008 Oct;20(10):1804-14
references.pmid: 18627789
references.citation: Growth Factors. 2007 Aug;25(4):253-63
references.pmid: 18092233
references.citation: J Clin Oncol. 2008 Jun 20;26(18):3051-6
references.pmid: 18565892
references.citation: Exp Cell Res. 2006 Feb 1;312(3):289-98
references.pmid: 16337626
references.citation: J Magn Reson Imaging. 2007 Dec;26(6):1618-25
references.pmid: 17968965
references.citation: J Clin Oncol. 2008 Jun 20;26(18):2999-3005
references.pmid: 18458039